Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment
Aardvark Therapeutics Inc. (NASDAQ:AARD) is one of the best young stocks with huge upside potential.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 3,917,299 | $51,414,550 | 6.92% | |
| 2. | Citadel Investment Group Ken Griffin | 1,289,263 | $16,921,577 | -6% | 0% |
| 3. | Laurion Capital Management Benjamin A. Smith | 1,014,911 | $13,320,707 | -4% | 0.5% |
| 4. | Millennium Management Israel Englander | 483,340 | $6,343,838 | +52% | 0% |
| 5. | SilverArc Capital Devesh Gandhi | 303,939 | $3,989,199 | -1% | 0.55% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.40 | 3,000 | $43,200.00 | 108,484 | 2025-12-11 | Filing | |
| $14.49 | 7,000 | $101,395.00 | 1,551,613 | 2025-12-11 | Filing | |
| $9.94 | 3,500 | $34,804.70 | 1,543,384 | 2025-09-15 | Filing | |
| $9.51 | 6,500 | $61,818.90 | 1,539,884 | 2025-09-15 | Filing | |
| $8.50 | 5,000 | $42,515.50 | 1,533,384 | 2025-09-12 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 784,430 | $10,295,643 | 0% | |
| 2. | 717,430 | $9,416,269 | 0% | |
| 3. | 476,595 | $6,255,309 | 5.71% | |
| 4. | 297,865 | $3,910,348 | 0% | |
| 5. | 158,240 | $2,076,900 | 0% |